Title: A phase II study investigating preoperative combination strategies for immunotherapy in patients with untreated, operable ER+, HER2-negative primary breast cancer
Disease site: Breast cancer
Status: Recruiting

Trial Design: International, open label, window of opportunity phase II trial that aims to evaluate the effects of immunotherapy-based treatment combinations in women with untreated, histologically confirmed, operable, oestrogen receptor positive, HER2-negative breast cancer. The study follows is designed with the flexibility to open new treatment arms as new treatments become available or modify the patient population. Eligible patients will be randomised with an approximately equal ratio (1:1:1:1) to one of four treatment arms: atezolizumab alone vs atezolizumab plus cobimetinib vs atezolizumab plus ipatasertib vs atezolizumab plus cobimetinib plus bevacizumab. Patients will receive treatment for 3 weeks prior to surgery or neoadjuvant therapy. Thereafter, patients will either be considered for definitive surgery or primary medical treatment (e.g. neoadjuvant therapy) at the discretion of the treating physician.

ECLIPSE aims to evaluate combinations of immune-modulatory agents in order to convert oestrogen positive tumours to inflamed phenotypes using short-term preoperative treatment strategies with tumour tissue samples collected pre- and on completion of treatment. Eclipse will also investigate correlations between the microbiome and outcome.

Trial details

Chief Investigator: Prof P. Schmid
Trial contact:
Clinical NCT03395899
EudraCT: 2016-004424-38
Sponsor: Queen Mary University of London
Participating countries: UK, Germany, South Korea
Source of funding: F. Hoffmann-La Roche Ltd (funding and study drug)

Clinical Trial Portfolio

Click here to to see a list of our clinical trials that are currently in set up or those that are open to recruitment.

Publications and presentations

Dynamic changes of PD-L1 and T-cell activation in ECLIPSE: A phase II study investigating preoperative immune combination strategies in untreated, operable ER+ primary breast cancer. Peter Schmid, Mark Kockx, Sung-Bae Kim, et al. Cancer Res February 15 2021 (81) (4 Supplement) PD14-06.